Can America Win The AI Biotech Race Against China? | Lada Nuzhna & Elliot Hershberg
Two venture capitalists dissect why biotech burns billions while China runs trials in weeks—and why the next Genentech won't look anything like the last one. Elliot Hershberg reveals the "three horsemen" strangling drug development as costs explode to $2.5 billion per approval, while Lada Nuzhna exposes how…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like The a16z Show →
Andreessen Horowitz's Vijay Pande: "AI doctors"
🔬Beyond AlphaFold: How Boltz is Open-Sourcing the Future of Drug Discovery
D.A. Wallach Explains Why Biotech VC Is So Different
E353: Why Biotech Is Struggling in Today’s Market (and the Future of Healthcare)
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.